| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
vTv Therapeutics Inc.$32.69
+0.81 (+2.54%)
B 76Pipeline Score Undervalued Pharma · Clinical
Market Cap
135.52 M
EPS
-0.63
P/E Ratio
-
Value Trade
779.51 K
SEC Financials
Q1 2026Dilution Risk
Revenue
36.84 M
R&D Expenses
8.98 M
Operating CF
9.15 M
Total Assets
98.81 M
Total Liabilities
8.85 M
Equity
89.96 M
D/E Ratio
12,345
-10.29 %
Week
-11.78 %
1 Month
-2.92 %
3 Month
13.81 %
6 Month
-65.18 %
5 Year
-93.86 %
All Time
Cash Data
Cash Position
98.09 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
124.26 K
52 Week Range
14 - 44
% held by Insiders
48.11 %
% held by Institutions
26.52 %
Enterprise Value
37.43 M
Total Shares
3.94 M
Short %
8.02 %
Float Shares
1.59 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for vTv Therapeutics Inc.
292Total events
1Upcoming
90Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 1
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 2
TBD
◆Enrollment CompleteCadisegliatinFiledTrial
Subscribe to view catalyst details
TBD
◆Oral PresentationCadisegliatinFiledPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-09-15 | Cadisegliatin (TTP399) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-09-15 | Cadisegliatin (TTP399) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-09-15 | Cadisegliatin (TTP399) | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
B76
Pipeline Score $2.0B
Pipeline ValueUndervalued
Valuation Signal8
Drugs Scored15.0x
rNPV / MCap Top 96%
Micro Cap (rank 37 of 912)
Percentile RankvTv Therapeutics Inc. holds a solid B-grade pipeline (76/100), with $40.5B risk-adjusted pipeline value, led by Cadisegliatin in Diabetes Mellitus, Type 1 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cadisegliatin Small molecule | Diabetes Mellitus, Type 1 | Phase 3 | NCT06334133 | 86% | $22.3B | RECRUITING | 150 | SLOW | B (66) | Oct 1, 2026 | MODERATE_RISK | LOW Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HPP737 | psoriasis | Phase 1 | 2021-06-29 | HPP737 was 10-100 fold more potent than apremilast in inhibiting the generation of cytokines/chemokines, depending upon the analyte. Read More | vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737 Read More | |
HPP737 | psoriasis | Phase 1 | 2021-06-29 | HPP737 was 10-100 fold more potent than apremilast in inhibiting the generation of cytokines/chemokines, depending upon the analyte. Read More | vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737 Read More | |
HPP737 | psoriasis | Phase 1 | 2021-06-29 | HPP737 was 10-100 fold more potent than apremilast in inhibiting the generation of cytokines/chemokines, depending upon the analyte. Read More | vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VTVT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VTVT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
vTv Therapeutics announced the granting of 2,500 stock options to a non-executive employee as an inducement to employment, in line with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30 and will vest over four years. The company is focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, currently in a Phase 3 trial.
Read more →VTVTvTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics reported its financial results for Q1 2026, highlighting progress in its Phase 3 CATT1 trial for cadisegliatin, an oral therapy for type 1 diabetes. The company expects to complete enrollment by Q3 2026 and has a solid cash position to support operations. Additionally, a recent license amendment has strengthened its financial standing.
Read more →VTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics Inc. has granted 39,500 stock options to two non-executive employees as an inducement under Nasdaq Listing Rule 5635(c)(4). The options, priced at an average of $32.00 per share, are intended to attract talent and will vest over four years. Cadisegliatin, the company's lead drug candidate for type 1 diabetes treatment, is currently undergoing a Phase 3 trial and has been designated as a Breakthrough Therapy by the FDA.
Read more →VTVTvTv Therapeutics to Participate in Upcoming May Investor Conferences
vTv Therapeutics Inc. announced its participation in two upcoming investor conferences in May 2026, focusing on its lead candidate, cadisegliatin, for type 1 diabetes. The company will engage in a fireside chat format at both events, providing updates on its clinical pipeline. Cadisegliatin is currently in a Phase 3 trial and has received Breakthrough Therapy designation from the FDA.
Read more →VTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 7, 2026
vTv Therapeutics announced the grant of 4,000 stock options to a non-executive employee as part of an inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $39.54 and will vest over four years. The company is advancing its lead candidate, cadisegliatin, a potential first-in-class treatment for type 1 diabetes, currently in a Phase 3 trial.
Read more →VTVT▲ +14.6%on this news
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
vTv Therapeutics Inc. announced its participation in the 38th Annual ROTH Conference, scheduled for March 22-24, 2026, in Dana Point, CA. The company will engage in a fireside chat and hold one-on-one investor meetings. Cadisegliatin, their lead candidate, is under investigation as a potential first-in-class oral adjunctive therapy for type 1 diabetes and is currently in a Phase 3 trial.
Read more →VTVTvTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete e
vTv Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a net loss of $27 million for the year. The company received an additional $20 million from Newsoara under a licensing agreement and expects to complete enrollment for its CATT1 Phase 3 trial by the third quarter of 2026. vTv has significantly strengthened its financial position, with increased cash reserves allowing for a funding runway beyond the anticipated topline readout. The firm continues to focus on the development of cadisegliatin for type 1 diabetes and has expanded its advisory board to support this effort.
Read more →VTVT▼ -7.2%on this news
vTv Therapeutics to Participate in Upcoming Investor Conferences
vTv Therapeutics Inc. announced its participation in two upcoming investor conferences, highlighting its focus on cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes. The company is currently conducting a Phase 3 trial for this drug, which has received Breakthrough Therapy designation from the FDA. However, the safety and efficacy of cadisegliatin remain unproven.
Read more →VTVT▲ +8.2%on this news
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
vTv Therapeutics has amended its license agreement with Newsoara Biopharma, granting Newsoara exclusive worldwide rights to develop and commercialize the PDE4 inhibitor HPP737. This strategic move includes a $20 million upfront payment and potential future milestone payments totaling approximately $115 million. The partnership aims to enhance the clinical development of HPP737, which has shown promise in treating inflammation-mediated diseases.
Read more →VTVTvTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
vTv Therapeutics announced the submission of a Phase 2 clinical study protocol for cadisegliatin, aimed at evaluating its effectiveness as an adjunctive therapy for type 2 diabetes, to the UAE Department of Health. The trial will be the longest for cadisegliatin, lasting 12 months with around 300 participants. vTv is collaborating with M42's IROS, which will fund the study, and the trial is expected to take place across the UAE, Jordan, and Tunisia starting in early 2026. The drug, a first-in-class oral glucokinase activator, has already received Breakthrough Therapy designation in the US but has yet to prove its safety and efficacy.
Read more →VTVTvTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
vTv Therapeutics has reported its third quarter financial results and provided updates on its cadisegliatin program. The company successfully completed an $80 million private placement and randomized its first patient in the Phase 3 CATT1 trial for type 1 diabetes. Additionally, a new U.S. patent for cadisegliatin has been issued, extending exclusivity until 2041. Topline results from the trial are expected in the second half of 2026.
Read more →VTVTvTv Therapeutics Announces New Appointments to its Scientific Advisory Board
vTv Therapeutics has appointed four prominent experts to its Scientific Advisory Board to provide strategic guidance on cadisegliatin, an oral adjunctive therapy for type 1 diabetes currently in Phase 3 trials. The new members bring extensive experience in endocrinology and diabetes research, which is expected to support the development and regulatory strategy of the drug. The company aims to innovate treatment options for individuals living with type 1 diabetes.
Read more →VTVTvTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
vTv Therapeutics will present at the INNODIA Symposium during the EASD 61st Annual Meeting. The company will share preclinical data on TTP-RA, an oral RAGE antagonist, and update on cadisegliatin, a potential first-in-class oral glucokinase activator in Phase 3 trials for type 1 diabetes. The presentation highlights vTv's commitment to developing innovative therapies for T1D.
Read more →VTVTUPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics Inc. announced its participation in several investor conferences this September. The company is focused on the development of cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes. Currently, cadisegliatin is in a Phase 3 trial, highlighting its advanced stage in clinical development.
Read more →VTVT▲ +13.3%on this newsshared move
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
vTv Therapeutics has announced an $80 million private placement to fund its ongoing CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes. The financing involves leading healthcare institutional investors and is expected to close shortly. Topline data from the trial is anticipated in the latter half of 2026.
Read more →VTVT▼ -6.4%on this news
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with da
vTv Therapeutics reported its second quarter financial results for 2025, highlighting the progress of its cadisegliatin program, with the first participant randomized in the Phase 3 CATT1 trial for type 1 diabetes. The company expanded its intellectual property portfolio and appointed a new CFO, showcasing internal growth. However, financial challenges were evident, with a reported net loss of $6.0 million and a significant decrease in cash reserves. Despite these setbacks, the company remains optimistic about cadisegliatin's potential to address unmet medical needs in diabetes care.
Read more →VTVT▲ +10.5%on this newsshared move
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
vTv Therapeutics announced that the USPTO has issued a Notice of Allowance for a patent covering cadisegliatin, a potential first-in-class oral therapy for Type 1 diabetes. This patent, which protects crystalline forms of cadisegliatin, extends through 2041. The company views this as a significant milestone in safeguarding their lead asset, which is currently undergoing Phase 3 trials.
Read more →VTVTvTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
vTv Therapeutics has announced the randomization of the first participant in its CATT1 Phase 3 trial for cadisegliatin, an oral adjunctive treatment for type 1 diabetes. This trial aims to evaluate the efficacy and safety of cadisegliatin in adults with T1D, with results expected in the second half of 2026. The study is significant as it addresses the lack of FDA-approved oral therapies for T1D.
Read more →VTVTvTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
vTv Therapeutics Inc. will participate in the H.C. Wainwright 'HCW@Home' Series on June 12, 2025. The event will feature a fireside chat with company management discussing their lead candidate, cadisegliatin, which is being investigated as a treatment for type 1 diabetes. This participation highlights vTv's ongoing commitment to developing therapies for chronic diseases.
Read more →VTVTvTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
vTv Therapeutics has appointed Michael Tung, M.D., MBA, as Chief Financial Officer. This appointment coincides with the reinitiation of the Phase 3 CATT1 trial for cadisegliatin, an oral adjunctive therapy for type 1 diabetes. Dr. Tung brings over 20 years of experience in finance and corporate strategy, which will be vital as the company advances its clinical programs.
Read more →VTVT▲ +5.2%on this newsshared move
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data
vTv Therapeutics has announced its first quarter financial results for 2025 and provided an update on its ongoing CATT1 Phase 3 trial for cadisegliatin, a potential adjunct therapy for type 1 diabetes. The company has reinitiated patient screening in the trial and expects to generate topline data by the second half of 2026, following an amendment to shorten the trial duration from 12 to 6 months. However, despite considerable progress, vTv reported a net loss and a decrease in cash reserves, which could impact future operations.
Read more →VTVT▲ +5.2%on this newsshared move
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
vTv Therapeutics has announced the reinitiation of screening in its CATT1 Phase 3 trial, focusing on cadisegliatin for treating type 1 diabetes. An amendment to the protocol has shortened the trial duration from 12 to 6 months, aiming to accelerate the timeline for topline data. The trial will assess the efficacy and safety of cadisegliatin, which has gained Breakthrough Therapy designation from the FDA. Approximately 150 patients will participate in this randomized, double-blind study, with topline results expected in the latter half of 2026.
Read more →VTVTvTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with typ
vTv Therapeutics announced its fourth quarter and full year financial results for 2024, highlighting the lifting of a clinical hold by the FDA on its cadisegliatin program. The Phase 3 CATT1 trial, targeting type 1 diabetes, is set to resume in Q2 2025 with an amended protocol that shortens the trial duration. The company has also strengthened its leadership team by appointing Martin Lafontaine as Chief Commercial Officer. Despite these advancements, vTv reported a significant net loss for the year, signaling financial challenges ahead.
Read more →VTVT▲ +53.1%on this newsshared move
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
vTv Therapeutics announced that the FDA has lifted the clinical hold on their cadisegliatin program, which is being investigated as an oral adjunct therapy for type 1 diabetes. The CATT1 Phase 3 trial is expected to resume, with a protocol amendment reducing its overall duration from 12 to 6 months. This change aims to expedite the initiation of larger pivotal studies for future New Drug Application submission. The safety and efficacy of cadisegliatin have not yet been established, and there is no guarantee of regulatory approval.
Read more →VTVTvTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
vTv Therapeutics Inc. announced its participation in the 7th Annual Evercore HealthCONx Conference, set to take place from December 3 to 5, 2024, in Coral Gables, Florida. Management will engage in a fireside chat and offer one-on-one meetings, showcasing their commitment to connecting with investors and stakeholders. The company is known for its clinical pipeline focused on a promising diabetes therapy. A live webcast of the presentation will also be available for interested parties.
Read more →VTVT▲ +7.6%on this news· ran to +35% by day 3
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. reported its financial results for the third quarter of 2024, highlighting a significant improvement in cash position to $41.6 million. The company provided an update on its cadisegliatin program, which is under clinical hold by the FDA while it seeks resolution on the issue. Financially, the net loss attributed to shareholders decreased compared to the same quarter last year, yet operational costs are rising with increased general and administrative expenses being noted. Overall, vTv continues to make strides in its clinical programs and financial management.
Read more →VTVTvTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D) working to resolve clinical hold Expanded New
vTv Therapeutics reported its financial results for Q2 2024, highlighting progress in its clinical pipeline, including the screening of the first patient in the pivotal trial for cadisegliatin aimed at treating type 1 diabetes (T1D). The company has amended its licensing agreement with Newsoara Biopharma to a global license for PDE4 inhibitor HPP737. However, the FDA has placed a clinical hold on the cadisegliatin program due to a chromatographic signal issue that requires further in vitro study. Despite these challenges, vTv maintains a strong cash position to support its development efforts.
Read more →VTVTvTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
vTv Therapeutics has announced that the FDA placed a clinical hold on its cadisegliatin program, impacting the ongoing CATT1 Phase 3 trial for type 1 diabetes. This hold stems from a chromatographic signal discovered in a recent ADME study that requires further characterization. Although cadisegliatin has shown a favorable safety profile in prior studies, the FDA needs additional data before the program can resume. The company is working with the agency to resolve the issue swiftly and is optimistic about cadisegliatin's potential as an oral therapy for type 1 diabetes.
Read more →VTVT▼ -8.6%on this news
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
vTv Therapeutics announced the screening of the first patient in its CATT1 pivotal trial for cadisegliatin, a potential first-in-class oral liver selective glucokinase activator for type 1 diabetes (T1D). The trial aims to evaluate the drug's efficacy and safety over 12 months and is expected to enroll around 150 patients. Cadisegliatin has already been administered to over 500 individuals, including those with T1D and type 2 diabetes (T2D). The successful outcome of this trial could lead to regulatory submission and new treatment options for diabetes management.
Read more →VTVT▲ +5.2%on this news
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. reported its financial results for the first quarter of 2024, marking significant milestones including a $51 million private placement to fund clinical trials. The company is advancing its Phase 3 study of cadisegliatin, an adjunctive therapy for type 1 diabetes, with top-line data expected by Q1 2026. Despite the positive developments, vTv also reported a net loss of $4.9 million, slightly higher than the previous year's loss of $4.5 million.
Read more →VTVTvTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics announced its financial results for Q4 2023 and the full year, highlighting a recent $51 million PIPE funding from institutional investors. The company plans to initiate patient enrollment for its Phase 3 clinical trial of cadisegliatin, an oral adjunctive therapy for type 1 diabetes, in Q2 2024. Additionally, vTv is preparing for a Phase 2 study in type 2 diabetes expected later this year. Despite a net loss of $20.3 million for 2023, the company emphasizes positive progress and potential for significant advancements in 2024.
Read more →VTVT▼ -15.3%on this news
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
vTv Therapeutics Inc. has announced the submission of a study protocol to the FDA for its first Phase 3 trial of cadisegliatin (TTP399) as an adjunct to insulin in adults with Type 1 Diabetes. This randomized, double-blind trial will include around 150 patients across 20 sites in the U.S., evaluating the drug's safety and efficacy compared to a placebo. Cadisegliatin is currently not approved anywhere globally and aims to fill the need for improved glycemic control in Type 1 Diabetes patients.
Read more →VTVT▼ -5.7%on this news· ran to -20% by day 1shared move
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
vTv Therapeutics Inc. will present at the TD Cowen 44th Annual Healthcare Conference in Boston from March 4-6, 2024. The company's presentation is scheduled for March 5, 2024, at 9:50 AM ET, and will be available via live webcast. vTv Therapeutics focuses on developing cadisegliatin (TTP399) as an adjunct therapy for type 1 diabetes. The company also indicates plans for additional indications, while cautioning about inherent risks in its forward-looking statements, particularly regarding financing and partnership opportunities.
Read more →VTVT▲ +95.9%on this news· ran to +106% by day 1shared move
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024
vTv Therapeutics announced the closure of a $51 million private placement from institutional investors, including the JDRF T1D Fund. The funds will fully finance the first Phase 3 clinical study of cadisegliatin, aimed at treating type 1 diabetes, which is expected to commence in mid-2024. The company expressed optimism about the potential benefits of cadisegliatin for individuals living with type 1 diabetes, highlighting the importance of additional therapies in this area. This funding and the addition of new board members signify a strategic move for vTv as it advances its clinical development plans.
Read more →VTVTvTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. reported its financial results for the third quarter of 2023, showcasing a significant net loss of $6.7 million. The company recently appointed Dr. Thomas Strack as Chief Medical Officer to lead the cadisegliatin Phase 3 program, which aims to advance treatment for type 1 diabetes. vTv also entered a stock repurchase agreement that resulted in $4.4 million in proceeds. However, despite these developments, the company's cash position decreased, and liabilities rose, highlighting potential financial challenges ahead.
Read more →VTVTvTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
vTv Therapeutics Inc. will participate in the Stifel 2023 Healthcare Conference, with presentation scheduled for November 15, 2023. The company's Chief Financial Officer, Chief Scientific Officer, and Chief Medical Officer will be attending to discuss cadisegliatin (TTP399), a therapy for type 1 diabetes. The presentation will be available via webcast, and there is an opportunity for one-on-one meetings with management. vTv Therapeutics aims to further develop their drug candidates, including pursuits in various health conditions.
Read more →VTVTvTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
vTv Therapeutics has appointed Dr. Thomas Strack as Chief Medical Officer, effective immediately. Dr. Strack brings extensive experience in drug development and has held various leadership positions within the pharmaceutical industry. His expertise is expected to facilitate the advancement of vTv's clinical programs, particularly for cadisegliatin, which is being developed as an adjunctive therapy to insulin for type 1 diabetes. The company is preparing to initiate Phase 3 study activities for this promising therapy.
Read more →VTVTvTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
vTv Therapeutics has announced a sale of its shares in Reneo Pharmaceuticals for approximately $4.4 million. This sale is part of a common stock repurchase agreement aimed at providing financial support for advancing the cadisegliatin Phase 3 program targeting type 1 diabetes. The company remains eligible for milestone payments and royalties from Reneo's lead product candidate, mavodelpar, which is currently in clinical trials. As vTv prepares for this next phase, they are also engaged in discussions regarding further financing and partnerships.
Read more →VTVTvTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics reported its financial results for the second quarter of 2023, highlighting progress on the development of cadisegliatin for type 1 diabetes. The company received Breakthrough Therapy Designation for cadisegliatin, which allows engagement with the FDA regarding a Phase 3 study. While the cash position improved slightly, vTv faced increased net losses and higher R&D and administrative expenses. The company is also working to comply with Nasdaq's minimum bid requirements by December 2023.
Read more →VTVT▲ +5.2%on this news
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
vTv Therapeutics announced that Cantex Pharmaceuticals has licensed exclusive rights from Georgetown University for azeliragon, aimed at treating cancer-related cognitive decline. Azeliragon, originally developed for Alzheimer's, has shown safety and tolerability in significant clinical trials. The collaboration aims to explore its potential benefits in alleviating cognitive decline resulting from chemotherapy. Additionally, Cantex is investigating azeliragon for various cancers and other conditions.
Read more →VTVTvTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
vTv Therapeutics has announced that the U.S. Patent and Trademark Office has issued a patent to Cantex Pharmaceuticals covering the use of azeliragon for glioblastoma multiforme (GBM) treatment. Azeliragon, previously under development for Alzheimer's, is now positioned for potential cancer applications, bolstered by FDA Orphan Drug Designation. Cantex is set to initiate clinical trials for glioblastoma, continuing its development across various cancers and conditions. The collaboration aims to maximize commercial opportunities for azeliragon if clinical trials prove successful.
Read more →VTVTvTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
vTv Therapeutics has announced its financial results for the first quarter of 2023, highlighting progress with its lead drug TTP399 aimed at treating type 1 diabetes. The company has secured approximately $12 million from G42 Investments, bolstering its cash reserves to nearly $18.8 million. Notably, vTv also reported a reduced net loss of $4.5 million compared to the previous year, alongside a confirmed FDA agreement on its pediatric study plan. However, challenges persist with increased R&D costs and a continuing stockholders' deficit.
Read more →VTVT▲ +16.3%on this news
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics has announced its 2022 fourth-quarter and full-year financial results, highlighting preparations for initiating Phase 3 clinical trials of TTP399 for Type 1 diabetes treatment. The company has strengthened its executive team with notable appointments and has received support from the FDA regarding its pediatric study plan. Financial results indicate a decrease in cash position and a notable net loss, though the latter is less than the previous year's loss. The company remains committed to advancing its clinical programs amidst its financial challenges.
Read more →VTVTElizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
vTv Therapeutics has announced the appointment of Elizabeth Keiley as Executive Vice President and General Counsel, effective immediately. Keiley brings extensive legal expertise from her roles at biotechnology and medical device companies, and she is expected to play a crucial role as the company prepares for pivotal studies of its treatment TTP399 for type 1 diabetes. vTv Therapeutics is approaching a key inflection point with the potential for commercialization in the near future.
Read more →VTVTNASDAQ: VTVT Improving the Lives of Millions of Patients with Type 1 Diabetes Non - Confidential vTv Therapeutics THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD - LOOKING STATEMENTS REGARDING (I) DIABETES M
vTv Therapeutics has introduced TTP399, a groundbreaking oral therapeutic aimed at improving the management of Type 1 Diabetes (T1D) for over 8 million patients worldwide. This drug is designed to work alongside insulin therapy to reduce low blood sugar events and enhance overall glycemic control. TTP399 has received FDA Breakthrough Therapy Designation, supporting its significance in diabetes treatment. The company is preparing for upcoming clinical trials that may further validate its efficacy and safety in treating patients with T1D.
Read more →VTVT▼ -11.4%on this news
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the a
Read more →VTVT▼ -11.4%on this news
Steven Tuch, Chief Financial Officer vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
Tuch, Chief Financial Officer vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer HIGH POINT, N.C. - December 13, 2022 - vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally
Read more →VTVTvTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and me
Read more →VTVT▲ +6.2%on this news
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to levera
Read more →VTVTvTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer HIGH POINT, N.C. - (GLOBE NEWSWIRE)
Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer POINT, N.C. - (GLOBE NEWSWIRE) - July 27, 2022 - vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for typ
Read more →VTVTvTv Therapeutics Announces Investment by CinRx Pharma HIGH POINT, N.C. (GLOBE NEWSWIRE)
vTv Therapeutics Announces Investment by CinRx Pharma HIGH POINT, N.C. (GLOBE NEWSWIRE) July 25, 2022 vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ( CinPax ), a subsidiary of CinRx Pharma, LLC (
Read more →VTVT▼ -9.2%on this news
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
HIGH POINT, N.C., June 04, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that the results from the JDRF-supported me
Read more →VTVT▲ +30.6%on this newsshared move
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare HIGH POINT, N.C.--(GLOBE NEWSWIRE)
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare HIGH POINT, N.C.--(GLOBE NEWSWIRE)-- June 1, 2022 -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 mill
Read more →VTVTvTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE)
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE) - May 12, 2022 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an upd
Read more →VTVTvTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE)
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE) - March 29, 2022 - vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended Decembe
Read more →VTVT▼ -6.7%on this news
vTv Therapeutics Shares Updated Corporate Presentation
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TT
Read more →VTVTvTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C., Dec. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical
Read more →VTVTvTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE)
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE) - November 9, 2021 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provide
Read more →VTVTvTv Therapeutics Announces Deepa Prasad as New President and
Therapeutics Announces Deepa Prasad as New President and CEO HIGH POINT, N.C., Oct. 20, 2021 at 9am (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabe
Read more →VTVT▼ -5%on this news
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported in the placebo arm Start-up activities for Phase 3 program ongoing with trials
Read more →VTVTvTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support advancement of HPP737 into Phase 2 in moderate to severe psoriasis. Successful pre-IND m
Read more →VTVTvTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE)
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - (GLOBE NEWSWIRE) - August 4, 2021 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an
Read more →VTVTvTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
HIGH POINT, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that it will be presenting data from
Read more →VTVTvTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
HIGH POINT, N.C. and WESTON, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights
Read more →VTVTvTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studie
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose
Read more →VTVTvTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
HIGH POINT, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that the U.S. Food and Drug Adminis
Read more →VTVTvTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
HIGH POINT, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using TTP399, the company’s oral glucokinase activator. The patent n
Read more →VTVTvTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mec
Read more →VTVTvTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
HIGH POINT, N.C., March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in th
Read more →VTVTvTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publicati
Read more →VTVTvTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
HIGH POINT, N.C., Feb. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) and inflammatory diseases, today announced that the results
Read more →VTVTvTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim, Newsoara Biopharma, has initiated a phase 2 study in COPD in China HIGH POINT, N.C., Feb
Read more →VTVTvTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
HIGH POINT, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating
Read more →VTVTvTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in
Read more →VTVTvTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. An
Read more →VTVTvTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional i
Read more →VTVTForward-Looking Statements This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including
vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital HIGH POINT, N.C.--(GLOBE NEWSWIRE)- November 24, 2020 -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement ("Purcha
Read more →VTVTvTv Therapeutics Announces 2020 Third Quarter Financial Results and Update HIGH POINT, N.C. - (GLOBE NEWSWIRE)
vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update HIGH POINT, N.C. - (GLOBE NEWSWIRE) - November 5, 2020 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the
Read more →VTVTvTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
HIGH POINT, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease (AD) in people with
Read more →VTVTvTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event
HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event on November 4, 2020. The presentation will provide a general stu
Read more →VTVTvTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study (NCT03335371) that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes (T1D). Newl
Read more →VTVTvTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
HIGH POINT, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at the 56th Annual Meeting of the European Associa
Read more →VTVTvTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
HIGH POINT, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Edward P. Taibi, Executive Vice President of MacAndrews & Forbes Incorporated (“MacAndrews”), to the vTv Board of Directors. Effective August 31, 2020, Mr. Taibi
Read more →VTVTvTv Therapeutics Announces 2020 Second Quarter Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE) - August 3, 2020 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020, and provided an update on the progre
Read more →VTVTvTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will hig
Read more →VTVTvTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) - HIGH POINT, N.C., June 13, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today made two prese
Read more →VTVTvTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions
HIGH POINT, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Assoc
Read more →VTVTvTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format
HIGH POINT, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and
Read more →VTVTvTv Therapeutics Announces 2020 First Quarter Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces 2020 First Quarter Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE) - May 7, 2020 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020, and provided an update on recent clinica
Read more →VTVTvTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Company Announced Positive Results from its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, De
vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Company Announced Positive Results from its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time
Read more →VTVTvTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
- TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis - Company to host investor conference call today at 8:30 a.m. ET HIGH POINT, N.C., Feb. 10, 2020 (GLOBE NEWSW
Read more →VTVTvTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes
Read more →VTVTvTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to p
Read more →VTVTvTv Therapeutics Announces 2019 Third Quarter Financial Results and Update SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer's disease
vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer's disease with type 2 diabetes actively enrolling HIGH POINT, N.C.
Read more →VTVTvTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York Cit
Read more →VTVTvTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
HIGH POINT, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the 55th Annual Meeting of the European Association for the Study of Di
Read more →VTVTvTv Therapeutics to Present Posters at Two Scientific Conferences in September
Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program HIGH POINT, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutica
Read more →VTVTvTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it is scheduled to present
Read more →VTVTvTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences
HIGH POINT, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it will be pa
Read more →VTVTvTv Therapeutics Announces 2019 Second Quarter Financial Results and Update HIGH POINT, N.C. - (GLOBE NEWSWIRE)
vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update HIGH POINT, N.C. - (GLOBE NEWSWIRE) - Jul. 31, 2019 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019, and provided an update on recen
Read more →VTVTvTv Therapeutics Announces 2019 First Quarter Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces 2019 First Quarter Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE) - May 1, 2019 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019, and provided an update on recent ac
Read more →VTVTvTv Therapeutics Announces $15 Million of Class A Common Stock Financings Proceeds Will Fund Start Up Activities for Current and Future Clinical Trials HIGH POINT, NC-(BUSINESS WIRE)
vTv Therapeutics Announces $15 Million of Class A Common Stock Financings Proceeds Will Fund Start Up Activities for Current and Future Clinical Trials HIGH POINT, NC-(BUSINESS WIRE)-March 18, 2019-vTv Therapeutics Inc. (Nasdaq:VTVT) (the "Company") today announced that it has
Read more →VTVTvTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update HIGH POINT, N.C. - (BUSINESS WIRE) - Feb. 27, 2019 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018, and p
Read more →VTVTDisclosure Notice The statements made in this presentation may include forward-looking statements regarding the Alzheimer's and diabetes markets, the development and attributes of investigational and marketed products to
vTv Therapeutics (VTVT) February 2019 NASDAQ: VTVT Exhibit 99.1 Disclosure Notice The statements made in this presentation may include forward-looking statements regarding the Alzheimer's and diabetes markets, the development and attributes of investigational and marketed produc
Read more →VTVTvTv Therapeutics Announces Third Quarter 2018 Results and Update HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces Third Quarter 2018 Results and Update HIGH POINT, N.C. - (BUSINESS WIRE) - Nov. 8, 2018 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter that ended September 30, 2018, and provided an update on recent achieve
Read more →VTVTvTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market HIGH POINT, N.C. - (BUSINESS WIRE) - Oct. 29, 2018 - vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treat
Read more →VTVTvTv Therapeutics Announces Second Quarter 2018 Results and Update HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces Second Quarter 2018 Results and Update HIGH POINT, N.C. - (BUSINESS WIRE) - August 3, 2018 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievem
Read more →VTVTvTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study HIGH POINT, N.C. - (BUSINESS WIRE) - June 12, 2018 - vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company's STEADFAST Study of the investigational medication
Read more →VTVTvTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights HIGH POINT, N.C. - (BUSINESS WIRE) - May 15, 2018 - vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial and operational results for the first quarter that ended March 31,
Read more →VTVTvTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer's Disease HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer's Disease HIGH POINT, N.C. - (BUSINESS WIRE) - April 9, 2018 - vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part
Read more →VTVTvTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights HIGH POINT, N.C. - (BUSINESS WIRE) - Feb. 27, 2018 - vTv Therapeutics Inc. (Nasdaq:VTVT) today provided a corporate update and reported financial and operational re
Read more →VTVTvTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results HIGH POINT, N.C. - (BUSINESS WIRE) - November 1, 2017 - vTv Therapeutics Inc. (vTv Therapeutics) (Nasdaq: VTVT) today provided a corporate update and reported financial and operational results for the
Read more →VTVTvTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results HIGH POINT, N.C. - (BUSINESS WIRE)
vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results HIGH POINT, N.C. - (BUSINESS WIRE) - August 2, 2017 - vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate update and reported financial and operational results for the second quarter
Read more →VTVTvTv Therapeutics Reports First Quarter 2017 Financial and Operational Results HIGH POINT, N.C.--(BUSINESS WIRE)
vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results HIGH POINT, N.C.--(BUSINESS WIRE)-- May 3, 2017 -- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administ
Read more →VTVTvTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer's Disease Posit
vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer's Disease Positive Phase 2 results for Type 2 diabetes therapies, TTP273
Read more →VTVTvTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes Oral small molecule GLP-1 receptor agonist met primary endpoint Company's second successful Phase 2 diabetes trial in 20
vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes Oral small molecule GLP-1 receptor agonist met primary endpoint Company's second successful Phase 2 diabetes trial in 2016 HIGH POINT, N.C.--(BUSINESS WIRE)--Dec. 14, 2016-- vTv
Read more →VTVTvTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights High Point, North Carolina (
vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights High Point, North Carolina (November 2, 2016) -- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new
Read more →VTVTvTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Company Releases Q2 Earnings Res
vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Company Releases Q2 Earnings Results and Details Upcoming Program Milestones High Point,
Read more →VTVTvTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes Novel glucokinase activator shows sustained meaningful reduction in HbA1c with well-tolerated tre
vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes Novel glucokinase activator shows sustained meaningful reduction in HbA1c with well-tolerated treatment regimen High Point, NC - August 10, 2016 - vTv Ther
Read more →VTVTvTv Therapeutics Reports First Quarter Financial and Operational Results High Point, N.C.
vTv Therapeutics Reports First Quarter Financial and Operational Results High Point, N.C. - May 12, 2016 - vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheime
Read more →VTVTvTv Therapeutics Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights - Launched pivotal Phase 3 STEADFAST study with azeliragon in Alzheimer's disease - Completed enrollment
vTv Therapeutics Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights - Launched pivotal Phase 3 STEADFAST study with azeliragon in Alzheimer's disease - Completed enrollment of AGATA Phase 2b study with liver-selective Glucokinase A
Read more →VTVTDisclaimer The statements made in this presentation may include forward-looking statements regarding the Alzheimer's disease and diabetes market, the future operations, opportunities or financial performance of vTv Thera
TREATMENTS FOR THE ADVANCEMENT OF LIFE INVESTOR PRESENTATION Exhibit 99.1 Disclaimer The statements made in this presentation may include forward-looking statements regarding the Alzheimer's disease and diabetes market, the future operations, opportunities or financial perform
Read more →VTVTvTv Therapeutics Reports Financial Results for the Third Quarter Ended
vTv Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2015 POINT, NC November 12, 2015 vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments
Read more →VTVTvTv Therapeutics Inc. (Nasdaq: VTVT) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, July 30, 2015 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs, will visit the Nasdaq MarketSite in Times Square to celebrate its
Read more →Competitive Position
How VTVT ranks across every disease it competes inCompetitive Position is a premium feature
See how VTVT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial